Sugi Predict

Sugi Predict / Compounds / SCHEMBL25316236

SCHEMBL25316236

SCHEMBL25316236

CC(C)(C)OC(=O)N1CCC2(CC1=O)CC(F)(F)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.38
▸ BUB1 O43683 1/20 0.35
▸ GRIN2B Q13224 1/20 0.33
▸ GRIN2C Q14957 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CYP11B2 P19099 1/20 0.32
▸ SCN5A Q14524 1/20 0.31
▸ SCN9A Q15858 1/20 0.31
▸ CHRM2 P08172 1/20 0.31
▸ CHRM1 P11229 1/20 0.31
▸ CHRM3 P20309 1/20 0.31
▸ HDAC2 Q92769 2/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ GPR119 Q8TDV5 2/20 0.31
▸ SCD5 Q86SK9 1/20 0.31
▸ DDB1 Q16531 2/20 0.30
▸ CRBN Q96SW2 2/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31480068 0.87 KDM1A (0.41) KDM1ABUB1GRIN2BGRIN2CUSP2
SCHEMBL25314667 0.85 KDM1A (0.37) KDM1ABUB1GRIN2BGRIN2CUSP2
SCHEMBL25319841 0.82 KDM1A (0.41) KDM1ABUB1USP2SMN1; SMN2CYP11B2
SCHEMBL31480399 0.80 CYP11B2 (0.38) KDM1AUSP2SMN1; SMN2CYP11B2HDAC2
SCHEMBL26496678 0.78 USP2 (0.40) KDM1ABUB1USP2SMN1; SMN2CYP11B2
SCHEMBL31480572 0.78 KDM1A (0.36) KDM1AUSP2CYP11B2GPR119
SCHEMBL16409307 0.78 BUB1 (0.42) KDM1ABUB1GRIN2BGRIN2CUSP2
SCHEMBL24569354 0.76 KDM1A (0.39) KDM1ABUB1GRIN2BGRIN2CUSP2
SCHEMBL3745682 0.76 BUB1 (0.37) KDM1ABUB1GRIN2BGRIN2CUSP2
SCHEMBL20870087 0.76 USP2 (0.49) USP2SMN1; SMN2CYP11B2HDAC2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115572-A1 SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS PHARMA AG (CH) 2025-04-10 — — US disclosed
WO-2025054361-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2025-03-13 — — WO disclosed
EP-4469157-A1 SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF Novartis AG (CH) 2024-12-04 — — EP disclosed
CN-118696035-A Spiropiperidyl derivatives as complement factor B inhibitors and their use 诺华股份有限公司 2024-09-24 — — CN disclosed
WO-2023139534-A1 SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2023-07-27 — — WO disclosed
WO-2023139534-A1 SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115572-A1 SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF CFB, C1QBP, CFH KDM1A 4756/4885BUB1 2710/4885GRIN2B 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.